Acetyl L-carnitine slows decline in younger patients with Alzheimer's disease: A reanalysis of a double-blind, placebo-controlled study using the trilinear approach

International Psychogeriatrics

Volumn 10, Issue 2, 1998, Pages 193-203

  Brooks III, John O ^a   Yesavage, Jerome A ^a,b   Carta, Angelico ^c   Bravi, Daniele ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c Sigma Tau Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVACECARNINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FLATULENCE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE REGRESSION; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TREATMENT OUTCOME; UNITED STATES;

ACETYLCARNITINE; AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; HUMANS; LINEAR MODELS; LONGITUDINAL STUDIES; MALE; MODELS, STATISTICAL; NOOTROPIC AGENTS; REGRESSION ANALYSIS; ROC CURVE;

EID: 0031927848     PISSN: 10416102     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1041610298005304     Document Type: Article

References (20)

1. Barnes, E. L., & Gray, S. L. (1998). Donepezil use in Alzheimer disease. Annals of Pharmacotherapy, 32, 70-77.
2. Brooks, J. O. III. (1993). The trilinear program: A program to analyze longitudinal change on the Macintosh. Behavior Research Methods, Instruments, and Computers, 25, 485-486.
3. Brooks, J. O. III, Kraemer, H. C., Tanke, E. D., & Yesavage, J. A. (1993a). The methodology of studying Alzheimer's disease. Journal of the American Geriatrics Society, 41, 623-628.
4. Brooks, J. O. III, & Yesavage, J. A. (1995). Identification of fast and slow decliners: A different approach. Alzheimer Disease and Related Disorders, 9(Suppl. 1), S19-S25.
5. Brooks, J. O. III, Yesavage, J. A., Taylor, J., Friedman, L., Tanke, E. D., et al. (1993b). Elaborating on the nature of the longitudinal factor structure of the Mini-Mental State Examination. International Psychogeriatrics, 5, 135-146.
6. Carta, A., & Calvani, M. (1991). Acetyl-L-carnitine: A drug able to slow the progress of Alzheimer's disease? Annals of the New York Academy of Sciences, 640, 228-232.
7. Galasko, D., Corey-Bloom, J., & Thal, L. J. (1991). Monitoring progression in Alzheimer's disease. Journal of the American Geriatrics Society, 39, 932-941.
8. Gelenberg, A. J. (1996). Developing drugs for Alzheimer's. Biological Therapies in Psychiatry Newsletter, 19(11), 41-42.
9. Imperato, A., Ramacci, M. T., & Angelucci, L. (1989). Acetyl L-carnitine enhances acetylcholine release in the striatum and hippocampus of awake freely moving rats. Neuroscience Letters, 107, 251-255.
10. Knapp, M.J., Knopman, D. S., Solomon, P. R., Pendlebury, W. W., Davis, C. S., et al. (1994). A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. Journal of the American Medical Association, 271, 985-991.
11. Kraemer, H. C. (1992). Evaluating medical tests: Objective and quantitative guidelines. Newbury Park, CA: Sage.
12. Lavretsky, E., Matsuyama, S. S., Gerson, S., & Jarvik, L. F. (1996). Genetics of geriatric psychopathology. In J. Sadovoy, L. W. Lazarus, L. F. Jarvik, & G. T. Grossberg (Eds.), Comprehensive review of geriatric psychiatry - II (pp. 43-79). Washington, DC: American Psychiatric Press.
13. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., et al. (1984). Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939-944.
14. Mohs, R. C., Rosen, W. G., & Davis, K. L. (1983). The Alzheimer's Disease Assessment Scale: An instrument for assessing treatment efficacy. Psychopharmacology Bulletin, 19, 448-450.
15. Parnetti, L. (1995). Clinical pharmacokinetics of drugs for Alzheimer's disease. Clinical Pharmacokinetics, 29, 110-129.
16. Parnetti, L., Gaiti, A., Mecocci, P., Gottfries, C. G., Santucci, C., et al. (1990). Effect of acetyl-L-carnitine on serum levels of cortisol and adrenocorticotrophic hormone and its clinical effect in patients with senile dementia of Alzheimer type. Dementia, 1, 165-168.
17. Rogers, S. L., & Friedhoff, L. T. (1996). The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia, 7, 293-303.
18. Sano, M., Bell, K., Cote, L., Dooneief, G., Lawton, A., et al. (1992). Double-blind parallel design pilot study of acetyl levocarnitine in patients with Alzheimer's disease. Archives of Neurology, 49, 1137-1141.
19. Spagnoli, A., Lucca, U., Mensco, G., et al. (1991). Long-term acetyl-L-carnitine treatment in Alzheimer disease. Neurology, 41, 1726-1732.
20. Thal, L. J., Carta, A., Clarke, W. R., Ferris, S. H., Friedland, R. P., et al. (1996). A 1-year placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology, 47, 705-711.